Erratum  by unknown
V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 3
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva lERRATUM
An error appeared in abstract PSY27, “Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult
primary immune thrombocytopenia (ITP) in France” by Laurent Chiche, François Lefrère, Maruit Chulikavit, Allison Perrin, Lee Stern,
Matthias Bischof, and Sandra Cohen (Value in Health 2011;14(7):A415). This poster was presented at the ISPOR 14th Annual European
Congress in Madrid, Spain on November 7th, 2011.
In lines 5–7 of the Results section, the sentence that reads, “Dividing mean cost per patient by response rates, cost per response was
€27,337 for romiplostim and €25,178 for rituximab.” should read:
“Dividing mean cost per patient by response rates, cost per response was €21,067 for romiplostim and €27,337 for rituximab.”
Additionally, in line 3 of the Methods section, “50x109/L” should read “50x109/L”. The correct full text of the abstract appears below:
Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP)
in France
Laurent Chiche1, François Lefrère2, Maruit Chulikavit3, Allison Perrin3, Lee Stern3, Matthias Bischof4, Sandra Cohen5
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Objectives: Romiplostim stimulates platelet production via the thrombopoetin-receptor and is recommended for second- and third-
line treatment of chronic ITP in adults. Traditional treatment options in this setting have included unapproved use of the immuno-
suppressant rituximab. This analysis assessed the cost per responder of romiplostim compared to rituximab in adult ITP patients in
France.
Methods: A decision analytic model was developed to estimate the six-month cost per patient responding to treatment. A systematic
literature review was performed to obtain response rates (achieving a platelet count 50x109/L) for each treatment. Romiplostim
patients received weekly administrations; rituximab patients received 4 weekly intravenous infusions. Resource utilization was based
on French and international treatment guidelines, and clinical expert opinion. Unit costs were derived from published literature and
French reimbursement lists, and included the costs of routine physician visits, treatment administration and emergency care. Non-
responders incurred the cost of rescue therapy (IVIg and prednisone) and hospitalizations/physician visits associated with bleeding-
related events (BREs).
Results: Although the comparability of existing literature for romiplostim and rituximab was limited, several fulfilled the literature
review selection criteria. Response rates were 83% and 62.5%, as per the romiplostim pivotal trial and a meta-analysis on rituximab,
respectively. Mean cost per patient for romiplostim and rituximab was €17,486 and €17,086, respectively. Dividing mean cost per
patient by response rates, cost per response was €21,067 for romiplostim and €27,337 for rituximab. The main cost-offsets were due to
reduced rescue therapy and BREs, with romiplostim resulting in a 23% reduction in cost per platelet response. Across sensitivity
analyses, romiplostim consistently produced a lower cost per response.
Conclusions: In adult ITP patients, romiplostim yields a lower cost per response over 6 months compared to rituximab, indicating
romiplostim represents an efficient use of resources for the French healthcare system.
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